Milestones in NSCLC

Welcome to the Resource Center “Milestones in Non-Small-Cell Lung Cancer (NSCLC)” launched by Elsevier and the Journal of Thoracic Oncology at the World Conference on Lung Cancer 2016 in Vienna.

Recent years have seen much progression in learning about the biology of lung cancer cells and the mechanisms that control their growth and spread. This has led to define biomarkers and oncogenic drivers, to develop new screening systems such as liquid biopsy and improving patients outcome with targeted strategies and immunotherapies.

The Resource Center “Milestones in NSCLC” is dedicated to providing you with groundbreaking discoveries in diagnosis and management of NSCLC. Our aim is to supply health care professionals with clinically relevant information to enhance knowledge about lung cancer and help meet the challenges faced in today’s medical practice.

Article of the month


New this month


New videos

  • WCLC 2016: Interview with Prof. Tom Stinchcombe

    Advisory Editor

    Immunotherapy with nivolumab and pembrolizumab or a combination therapy have shown improvements in the survival of patients with squamous non-small-cell lung cancer. With many immunotherapeutic agents in the developmental phase, assigning patients to the best therapy will become ever more important and challenging.
  • WCLC 2016: Interview with Prof. Nir Peled

    Advisory Editor

    Biomarker testing has opened the door for precision medicine based on an individual patient’s tumor characteristics rather than histology alone. Key biomarkers in patients with advanced non-small-cell lung cancer are epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) gene rearrangements, KRAS mutations or programmed death-ligand 1 (PD-L1) expression. Limitations to this approach, e.g. the sensitivity of the diagnostic tools or tissue availability, should be overcome by modern molecular technologies.
  • WCLC 2016: Interview with Prof. Martin Reck

    In this video, Martin Reck, Head of the Oncology unit, LungenClinic Grosshansdorf, Germany, discusses the emergence of immunotherapy and the positive results of four randomized trials on immunotherapy vs. chemotherapy, showing benefit in overall survival. He also mentions that immunotherapy might work better than chemotherapy in selected patients and reviews treatment options for a specific population of patients with autoimmune diseases at baseline.
  • WCLC 2016: Interview with Prof. Federico Cappuzzo

    Therapy of EGFR-mutated lung cancer was discussed in detail during the World Conference on Lung Cancer held in Vienna, including recent data. Federico Cappuzzo, Director Medical Oncology Department at Ospedale Civile, Livorno, Italy, provides insights into the management of EGFR-mutated NSCLC with the new molecule osimertinib and reviews the benefits and limitations of liquid biopsy.

Stay informed

Subscribe to our E-Alert to keep up to date with the new items in the Resource Centre

Society partner

Made possible by an educational grant from

Please note that Lilly Oncology has no editorial control over the content of this Resource Centre. The Resource Centre and all content therein has been subjected to an independent editorial review.

Perspectives in Lung Cancer 2017

How I optimize treatment for my NSCLC patients with advanced and aggressive disease


Hotel Meliã Avenida América,
Madrid, Spain


Friday, March 3rd, 2017
11:40 - 13:10

ECCO 2017

Debating the optimal management in advanced and metastatic lung cancer: The right treatment for the right patient at the right time


Did you miss the Satellite Symposium?

Coming soon: Webcast on demand


This educational activity is provided by Elsevier. Independent sponsorship for this educational activity was provided by Lilly Oncology.

Interactive Case Reports

Read more about recent cases from the Journal of Thoracic Oncology. Test your knowledge and answer the questions following the case to get immediate feedback.

Solange Peters

Editor in Chief

Tom Stinchcombe

Advisory Editor

Nir Peled

Advisory Editor

Stefan Zimmermann

Managing Editor

About the Editors

All content available on the Milestones in NSCLC Resource Centre, including original and review articles, interviews, guidelines, congress highlights, case reports is independently selected by the members of the Editorial Board.